CNV2197944 / Biogen - LARVOL DELTA

A phase 1 ready novel sodium channel blocker CNV1061436 for CNS disorders is added to the pipeline of clinical development candidate (PipelineReview) - "Convergence expects to report data from the TN trial with CNV1014802 and the postherpetic neuralgia Phase II study with CNV2197944, in the first half of 2014."

Anticipated P2 data • Pain

Convergence Pharmaceuticals initiates phase I multiple ascending dose study for CNV2197944 (PRNewswire) - P1, N=NA; Convergence announces initiation of multiple ascending dose P1 study of CNV2197944, for the treatment of chronic pain; The study is expected to conclude in Q2 2012; The first human single ascending dose P1 study data demonstrated ideal pharmacokinetic profile and excellent safety and tolerability; CNV2197944 is proposed for development initially as a treatment for neuropathic pain and pain associated with osteoarthritis

Anticipated P1 data • P1 preliminary data • P1 trial initiation • Pain

Efficacy and Safety of CNV2197944 Versus Placebo in Patients With Post-herpetic Neuralgia (clinicaltrials.gov) - P2; N=103; Completed; Sponsor: Convergence Pharmaceuticals; Active, not recruiting -> Completed

Trial completion • Biosimilar • Pain